 LAVAL, QC and CAMBRIDGE, England, June 4, 2021 PRNewswire - Liminal BioSciences Inc. Nasdaq: LMNL Liminal BioSciences or the Company announced today that the U.S. Food Drug Administration FDA has approved Ryplazim plasminogen, human-tvmh Ryplazim for the treatment of patients with plasminogen deficiency type 1 hypoplasminogenia through its subsidiary, Prometic Biotherapeutics Inc., holder of the biological license application BLA for Ryplazim. With this approval, Ryplazim becomes the first FDA approved therapy for this rare genetic disorder. 